ArticlebioRxiv : the preprint server for biology2026
MicroRNA-181 influences Alzheimer's risk by regulating neprilysin and microtubule-associated tau pathways, offering a novel target.
Ruizhi Wang, Bryan Maloney, Kwangsik Nho, John S Beck, Scott E Counts, Debomoy K Lahiri
Abstract readPreprint
In one paragraphArticle in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
6 authors.
Ruizhi WangLaboratory of Molecular Neurogenetics, Departments of Psychiatry, Stark Neuroscience Research Institute, Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine, Indianapolis, IN, USA.
Bryan MaloneyLaboratory of Molecular Neurogenetics, Departments of Psychiatry, Stark Neuroscience Research Institute, Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine, Indianapolis, IN, USA.ORCID 0000-0003-2364-9649 Kwangsik NhoDepartment of Radiology & Imaging Sciences, Stark Neuroscience Research Institute, Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine, Indianapolis, IN, USA.ORCID 0000-0002-7624-3872 John S BeckDepartments of Translational Neuroscience and Family Medicine, Michigan State University, Grand Rapids, MI, USA.
Scott E CountsDepartments of Translational Neuroscience and Family Medicine, Michigan State University, Grand Rapids, MI, USA.ORCID 0000-0003-2851-9763 Debomoy K LahiriLaboratory of Molecular Neurogenetics, Departments of Psychiatry, Stark Neuroscience Research Institute, Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine, Indianapolis, IN, USA.ORCID 0000-0002-1664-5933 Funding
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0MTAU, AB, SYNUCLEIN AND NITRATIVE/OXIDATIVE DAMAGE IN MCIP01AG014449 · NIA · UNIVERSITY OF PITTSBURGH · PI MUFSON, ELLIOTT JAY · 1997 to 2024
$39.7MResearch Education ComponentP30AG072976 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI ANDREW J SAYKIN · 2021 to 2026
$24.1MRole of microRNA in regulating Fe, Amyloid, and Tau (FeAT) in Alzheimer's diseaseR56AG072810 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI LAHIRI, DEBOMOY K · 2021 to 2021
$630kNeurobiological Role of MicroRNA in Alzheimer'sR56AG051086 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI LAHIRI, DEBOMOY K · 2023 to 2023
$627kBrain protein alteration by vascular overexpressed miRNA (BravomiR)R21AG076202 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI LAHIRI, DEBOMOY K · 2022 to 2022
$435kTesting a Novel Approach to Solve the On-target, Off-site Effects of Alzheimer's DrugsR21AG056007 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI LAHIRI, DEBOMOY K · 2019 to 2020
$435kAlzheimer's disease-linked microRNA Exploration of UTR Polymorphisms (AdmiRE-UP)R21AG074539 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI LAHIRI, DEBOMOY K · 2022 to 2022
$435kNIA NIH HHS P01 AG014449NIA NIH HHS P30 AG072976NIA NIH HHS R21 AG056007NIA NIH HHS R21 AG074539NIA NIH HHS R21 AG076202NIA NIH HHS R56 AG051086NIA NIH HHS R56 AG072810NIA NIH HHS U01 AG024904
6 · The paper itselfAbstract
Alzheimer's disease (AD) is characterized by amyloid-β (Aβ) peptide plaques and neurofibrillary tangles from hyperphosphorylated tau, though factors linking amyloid and tau pathology remain unclear. We investigated whether microRNA-181d-5p (miR-181d) associates with AD-related brain changes and regulates neprilysin and tau. Modeling miR-181d across individuals with no cognitive impairment, mild cognitive impairment, and AD revealed region- and sex-specific associations. Higher miR-181d levels associated with greater AD probability in the temporal lobe and cerebellum, and lower probability in the posterior cingulate cortex of males; miR-181c attenuated these probabilities. SNPs near MIR181 associated with altered entorhinal cortical thickness. In cellular models, miR-181 reduced neprilysin 3'-UTR activity, mRNA, protein, and enzymatic activity, while increasing tau mRNA and protein. Neprilysin diminution impairs Aβ clearance and elevates tau, contributing to AD. RNA sequencing identified miR-181d-responsive neurodegenerative pathways. These findings identify miR-181 as a regulator of AD-relevant amyloid and tau pathways, providing novel targets.
Indexed as
Agingamyloiddementiagenetic variantsmicroRNAneprilysinSNPstauUTR
Identifiers
PMID42368021
PMCPMC13307934
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390